Not all anti-TNF-α agents have demonstrated therapeutic efficacy in IBD, with Etanercept a genetically engineered fusion protein fused with the Fc domain of human IgG1 demonstrating no benefit over placebo [89]. The gene discussed is TNF; the disease is inflammatory bowel disease.